"We are executing with urgency and purpose as we advance our pipeline assets to the clinic as expeditiously as possible," said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. "We are ...

ORLANDO, FL / ACCESS Newswire / April 10, 2026 / RedChip Companies, an industry leader in investor relations, media, ...

In 2026, AI will gain traction in life sciences and biopharmaceuticals, but the key to success is AI that goes deep into the ...

RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today ...

Opus Genetics and Viatris (through its affiliate) are parties to a global licensing agreement which provides for the development of phentolamine ophthalmic solution 0.75% and grants exclusive rights ...

ORLANDO, FL / ACCESS Newswire / April 2, 2026 / RedChip Companies, an industry leader in investor relations, media, and ...

The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. William Maguire discussing regulatory considerations related to PSMA PET imaging in clinical trials.

Lead candidate, CBT-001 for the treatment of pterygium, a multi-billion-dollar addressable market, is in mid-Phase 3 with ...

Galapagos And Gilead Enter Into Binding Agreement To Collaborate On Advancing First In Class T Cell Engager Program For Autoimmune Diseases. New collaboration structure achieves meaningfully improved ...

New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining ...

The newly released ACC/AHA/Multi-society Dyslipidemia Guidelines, along with other recent scientific statements, ii,iii also reiterated that fibrates are not recommended for routine use to reduce ...

For the past 7 years, pharmaceuticals that work as glucagon-like peptide 1 (GLP-1) receptor agonists have dominated the weight-loss and diabetes markets. These drugs, currently so ...